Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.

 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

Alzheimer's Disease Research - Current Awards

Dr. Kathryn Moore

Kathryn Moore, Ph.D.

Massachusetts General Hospital
Boston, MA

Title: Innate immune signaling in Alzheimer's disease pathogenesis
Non-Technical Title: Role of the innate immune response in the development of Alzheimer's disease
Duration: April 1, 2008 - March 31, 2011

Summary: This award seeks to study the role of the innate immune system in AD pathogenesis. and the role of Toll-like recceptors in mediating the microglial inflammatory response. Microglia likely play a key role in the clearance of Aß as well as in more chronic inflammatory changes as a result of Aß activation.
More details

Program: Alzheimer's Disease
Award Type: Standard
$265,000



Photo Pending

Robert Nichols, Ph.D.

Drexel University
Philadelphia, PA

Title: Beta Amyloid Regulation of Presynaptic Nicotinic Current
Non-Technical Title: Understanding the normal functions of Amyloid Beta
Duration: April 1, 2007 - March 31, 2010

Summary: This project is aimed at understanding the physiological role of Amyloid beta. Using a defined nerve cell system in culture, we can express target protein receptors for beta amyloid and then examine the functional consequence via several techniques. We can also introduce mutations into the receptors or make deletions to define precisely the molecular components targeted by beta amyloid. Finally, we can explore derivatives of beta amyloid as potential means to disrupt beta amyloid’s action
More details

Program: Alzheimer's Disease
Award Type: Pilot
$145,059



Dr. Marguerite Prior

Marguerite Prior, Ph.D.

The Cleveland Clinic Foundation
Cleveland, OH

Title: Inhibition of RTN3 aggregation as a novel therapeutic target to reduce cognitive failure in AD
Non-Technical Title: Novel therapeutic target to reduce cognitive failure in AD
Duration: April 1, 2008 - March 31, 2010

Mentor:
Riqiang Yan, Ph.D.
The Cleveland Clinic Foundation

Summary: This study hypothesizes that aggregation of a BACE inhibitor (RTN3) may lead to increased levels of amyloid beta. By defining a class of potential inhibitors of RTN3 aggregation, this proposal seeks to determine a new class of therapeutic interventions against Alzheimer's disease.
More details

Program: Alzheimer's Disease
Award Type: Research Fellowship
$100,000



Dr. Wolfgang Quitschke

Wolfgang Quitschke, Ph.D.

State University of New York at Stony Brook
Stony Brook, NY

Title: Effect Of Serum-Solubilized Curcumin On Plaques In Alzheimer’s Disease Transgenic Mice
Non-Technical Title: Effect Of Injectable Derivatives Of The Turmeric Spice On Plaques In AD Transgenic Mice
Duration: April 1, 2009 - March 31, 2011

Summary: Experimentally, curcumin (turmeric spice) has been implicated in resolving and preventing Alzheimer’s disease associated plaques or deposits both in living systems and in test tubes. Epidemiological data suggest that the consumption of curcumin is linked to a lower incidence of Alzheimer’s disease. However, the solubility of curcuminc in watery solutions is exceedingly low, which limits its systemic absorption and therapeutic potential. A new method is proposed to treat or prevent amyloid plaque formation associated with Alzheimer’s disease by injection of highly concentrated blood serum-solubilized curcumin.
More details

Program: Alzheimer's Disease
Award Type: Pilot
$104,762



Dr. Anton Roebroek

Anton Roebroek, Ph.D.

Katholieke Universiteit Leuven
Leuven, Belgium

Title: The Dual Role of LRP1 in Generation and Clearance of Ab
Non-Technical Title: Role of LRP1 in production and degradation of ABeta
Duration: April 1, 2007 - March 31, 2010

Summary: Recent scientific investigations revealed that a receptor, LRP1, present on the outside of the cells in the brain might be involved at the same time in both production and breakdown of Ab. Lately, the applicant of the research project generated mice and cells with a modified LRP1, which can be used to clarify the double role of LRP1 in Ab metabolism.
More details

Program: Alzheimer's Disease
Award Type: Standard
$240,000



Dr. Troy Rohn

Troy Rohn, Ph.D.

Boise State University
Boise, ID

Title: Caspase-cleavage of Tau in Alzheimer's disease
Non-Technical Title: Understanding relationship between ABeta and Tau in tangle formation
Duration: April 1, 2007 - March 31, 2010

Co-Investigator(s):
Wayne Poon, Ph.D.
University of California - Irvine

Summary: Direct, functional evidence for the involvement of caspases in driving AD pathology is currently lacking. The current proposal will test directly the role of caspases in AD by blocking caspase activation in an AD transgenic mouse model and examining whether such inhibition prevents the pathology associated with these animals.
More details

Program: Alzheimer's Disease
Award Type: Pilot
$131,140



Dr. Terrone Rosenberry

Terrone Rosenberry, Ph.D.

Mayo Clinic Jacksonville
Jacksonville, FL

Title: Detection of cross-linked amyloid-beta oligomers in Alzheimer's disease by mass spectrometry
Non-Technical Title: Is a specific chemical modification of amyloid beta-peptides important in Alzheimer's disease?
Duration: April 1, 2008 - June 30, 2010

Summary: This study seeks to determine some of the mechanisms by which amyloid beta aggregates and ultimately how these aggregates work to assemble in amyloid plaques. Using a systematic approach, Dr. Rosenberry's team is working on developing ways of studying these aggregates that exist at extremely low concentrations in the brain.
More details

Program: Alzheimer's Disease
Award Type: Pilot
$150,000



Dr. Paul Salvaterra

Paul Salvaterra, Ph.D.

Beckman Research Institute of the City of Hope
Duarte, CA

Title: Ab and Neurodegeneration
Non-Technical Title: Ab and neurodegeneration
Duration: April 1, 2007 - March 31, 2010

Summary: Our work is designed to investigate the role of certain peptides, both alone and in combination, as direct causes of chronic brain cell death. We will accomplish this by using a simplified genetically controlled model organism. We also believe that our preliminary observations indicate a new cellular pathway that may be responsible for Alzheimer's related cell death. We will thus try and prove this hypothesis using genetic and drug based experimental strategies in our model system.
More details

Program: Alzheimer's Disease
Award Type: Standard
$400,000



Photo of Dr. Eric Schon

Eric Schon, Ph.D.

Columbia University
New York, NY

Title: ER-Mitochondrial interactions in familial Alzheimer's disease
Non-Technical Title: Mitochondrial defects in familial Alzheimer’s disease
Duration: April 1, 2008 - March 31, 2010

Summary:
More details

Program: Alzheimer's Disease
Award Type: Pilot
$150,000



Photo Pending

Vijay Sharma, Ph.D.

Washington University
St. Louis, MO

Title: Imaging PGP-Mediated Transport in Alzheimer's Disease
Non-Technical Title: Improving imaging tools for diagnosis of AD
Duration: April 1, 2007 - March 31, 2010

Summary: We propose to evaluate the potential of lead Pgp-targeted agent to act as noninvasive probe to detect those defects in brains of mouse models via PET imaging. Additionally, our strategy is amenable to kit formulation with potential for widespread deployment of a test for managing AD.
More details

Program: Alzheimer's Disease
Award Type: Pilot
$150,000



Items 31 - 40 of 57  Previous123456Next

Last Reviewed On: 09/11/09